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Abstract
The main objective of the study was to evaluate neuraminidase inhibiting (NI) antibodies
against A/H1N1pdm09 influenza viruses in the community as a whole and after infection.
We evaluated NI serum antibodies against A/California/07/09(H1N1)pdm and A/South
Africa/3626/2013(H1N1)pdm in 134 blood donors of different ages using enzyme-linked lec-
tin assay and in 15 paired sera from convalescents with laboratory confirmed influenza. The
neuraminidase (NA) proteins of both A/H1N1pdm09 viruses had minimal genetic diver-
gence, but demonstrated different enzymatic and antigenic properties. 5.2% of individuals
had NI antibody titers1:20 against A/South Africa/3626/2013(H1N1)pdm compared to
53% of those who were positive to A/California/07/2009(H1N1)pdm NA. 2% of individuals
had detectable NI titers against A/South Africa/3626/13(H1N1)pdm and 47.3% were posi-
tive to A/California/07/2009(H1N1)pdm NA among participants negative to hemagglutinin
(HA) of A/H1N1pdm09 but positive to seasonal A/H1N1. The lowest NI antibody levels to
both A/H1N1pdm09 viruses were detected in individuals born between 1956 and 1968. Our
data suggest that NI antibodies against A/South Africa/3626/13 (H1N1)pdm found in the
blood donors could have resulted from direct infection with a new antigenic A/H1N1pdm09
variant rather than from cross-reaction as a result of contact with previously circulating sea-
sonal A/H1N1 variants. The immune responses against HA and NA were formed simulta-
neously right after natural infection with A/H1N1pdm09. NI antibodies correlated with virus-
neutralizing antibodies when acquired shortly after influenza infection. A group of middle-
aged patients with the lowest level of anti-NA antibodies against A/California/07/2009
(H1N1)pdm was identified, indicating the highest-priority vaccination against A/H1N1pdm09
viruses.
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Introduction
According to WHO-recognized National Influenza Centers in Moscow and Saint Petersburg,
2015/2016 epidemic season in Russia characterized by rapid increase of influenza and acute
respiratory infection (ARI) morbidity from week 3 of 2016. Increases in influenza-like illness
and hospitalization rates were similar to those observed during the 2009 pandemic and epi-
demic in 2010–2011 and were much higher than in other seasons [1]. According to the phylo-
genetic analysis of amino acid sequences of the main antigenic glycoprotein hemagglutinin
(HA), many of A/H1N1 viruses isolated in Russia in 2015–2016 belong to the clade 6B of A/
H1N1pdm09 (A/South Africa/3626/2013-like) [1]. Antibodies directed against HA provide
the main protection against influenza illness. However, as it was shown in 1973, antibodies
against minor immunogenic viral glycoprotein, neuraminidase (NA), can also provide protec-
tion against influenza infection [2]. Namely, antibodies against NA block viral progeny release
from cells during detachment of mature viral particles from the cell surface. At the initial stage
of influenza infection cycle, anti-NA antibodies may prevent connection of HA with cellular
receptors [3], block proapoptotic NA function [4], and inhibit NA plasminogen activation [5].
Furthermore, antibodies against NA can facilitate recognition of infected cells by macrophages
and natural killer (NK) cells, mediating the activation of the complement system during com-
plement-dependent cytotoxicity [6].
The hemagglutination-inhibition (HI) assay is most commonly used to assess previous
exposure and protective immunity to influenza viruses as well as to evaluate influenza vaccine
immunogenicity. However, the presence of NA inhibiting (NI) antibodies is the least explored.
The 2009 influenza pandemic caused by A/H1N1pdm09 initiated a number of studies on the
antibodies against viruses containing the N1 NA. The importance of NA immunity against
naturally occurring influenza was previously demonstrated by evaluating HI and NI antibody
titers in a study conducted during 2009–2011 [7]. The presence of a population possessing the
cross-reactive NI antibodies, which were acquired as a result of previous infection or vaccina-
tion with previously circulated influenza viruses, can be decisive in reducing illness and mor-
tality, as shown during a pandemic caused by the A/H3N2 virus in 1968 [2]. In addition, a
number of studies were conducted to identify cross-reactive anti-NA antibodies against the
new influenza virus like A/H1N1pdm09 [8] and to examine the formation and function of pro-
tective antibodies against NA by immunization with influenza vaccines [9, 10]. At the WHO
meetings in 2005 and 2009, leading experts noted the increasing importance of developing and
improving methods for detection of antibodies against influenza virus NA [11]. It is important
to study immunity against NA because NI antibodies are considered to be independent predic-
tors of anti-influenza immunity [7, 8]. The aim of the present study was to evaluate serum
anti-NA antibodies against two A/H1N1pdm09 strains, A/California/07/09 (H1N1)pdm and
A/South Africa/3626/2013 (H1N1)pdm, in the Russian population.
Materials and methods
Viruses
To evaluate the NI antibodies against A/H1N1pdm09 viruses, we developed chimeric viruses
with HA non-relevant to seasonal influenza viruses. The A/H7N1 reassortant virus containing
HA from A/horse/Prague/1/56 (H7N7) and NA from A/California/07/2009 (H1N1)pdm was
prepared using classical genetic reassortment in developing chick embryos as described else-
where [12]. The A/H6N1 virus harboring HA gene from A/herring gull/Sarma/51c/2006
(H6N1) and NA from A/South Africa/3626/13 (H1N1)pdm was generated using a standard
plasmid-based genetic technique [13].
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Influenza A/horse/Prague/1/56 (H7N7) virus and the live-attenuated A/H1N1 reassortant
with a 6:2 genome composition carrying HA and NA genes from A/South Africa/3626/13
(H1N1)pdm [14] were provided by the Centers for Disease Control and Prevention (CDC)
(Atlanta, USA). The wild-type A/South Africa/3626/2013 (H1N1)pdm virus was obtained
from the National Institute for Biological Standards and Control (NIBSC, UK) repository. The
A/herring gull/Sarma/51c/2006 (H6N1) virus was supplied by the Institute of Influenza, Saint
Petersburg, Russia. A/California/07/2009 (H1N1)pdm, A/New Caledonia/20/99 (H1N1) (A/
NC) and A/Puerto Rico/8/34 (H1N1) (A/PR/8) were provided by the Institute of Experimental
Medicine. All viruses were grown in the allantois cavity of 10-day developing chicken embryos
supplied by “Sinyavino” poultry farm (Kirovsk Area, Leningrad Region, Russia) at the 33˚C
for 48 h, aliquoted, and stored at -70˚C.
Sequence analysis
The DNA-copies of the viral RNA segments were obtained using the OneStep RT-PCR Kit
(Qiagen, Netherlands). Following the electrophoresis of the DNA-copies in 1.5% agarose gel
and consecutive purification by QIAquick PCR purification Kit (Qiagen), the sequencing was
conducted on DNA-analyzer ABI 3730xl using the BigDye Terminator v3.1 Cycle Sequencing
kit (Applied Biosystems, USA). The processing of the nucleotide sequence data was performed
using the 3730 Data Collection v3.0 software package (Applied Biosystems).
Molecular analysis
Multiple alignments and the identity analysis of the NA amino acid sequences from various A/
H1N1 influenza viruses were carried out using the GeneDoc program, version 2.6.002. The
amino acid sequences of the NA proteins were obtained from GenBank and the Global Initia-
tive on Sharing All Influenza Data (GISAID) database. Nucleotide sequences used in this study
are available under the following accession numbers: FJ984386, KF648099, KU509643.1,
AF250356, CY033624, AB671290, CY022071, EU124136, CY058489, CY044367, CY022351,
AF250363, CY061831, GU984385, GU367316, GQ183619, CY050881, HM189306, GU984412,
FJ798780, EU045389, GQ484356. Computer analysis was carried out using UGENE software
from Unipro (Russia, Novosibirsk) [15].
NA enzyme activity and kinetics
The NA activity of influenza H1N1 viruses was measured by a fluorescence-based assay using
the fluorogenic substrate MUNANA (Sigma-Aldrich, USA), based on the method of Potier
et al. [16] as described previously [17]. Briefly, A/California/07/09 (H1N1)pdm and A/South
Africa/3626/2013 (H1N1)pdm viruses were standardized to an equivalent NA protein content
of 0.015 ng/μl as determined by protein gel electrophoresis using purified and concentrated
viruses. This virus dilution was selected as a dilution that converted15% MUNANA sub-
strate to product during the reaction time in order to meet the requirements for steady-state
kinetic analysis [17]. Virus dilutions were prepared in enzyme buffer [32.5 mM of 2-(N-mor-
pholino) ethanesulfonic acid (MES), 4 mM of calcium chloride, pH 6.5] and added (100 μl/
well) in duplicate to a flat-bottom 96-well opaque black plate (Corning, USA). After preincu-
bation for 20–30 min at 37˚C, the MUNANA substrate at various concentrations (separately
pre-incubated for 20–30 min at 37˚C) was added to all wells (50 μl/well). Immediately after
adding the MUNANA substrate, the plate was transferred to a 37˚C pre-warmed SpectraMAX
Gemini XPS microplate reader (Molecular Devices, USA) and fluorescence was measured
every 60 s for 60 min at 37˚C, using excitation and emission wavelengths of 360 nm and 460
nm, respectively. Enzymatic reactions were performed under conditions where signal-to-noise
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ratios were above 10 during more than 30 min of the reaction time. Time course data from
each concentration of the MUNANA substrate were examined for linearity by linear regres-
sion analysis. Data with R2>0.99 were used for analysis. The kinetic parameters Michaelis-
Menten constant (Km) and maximum velocity of substrate conversion (Vmax) of the NAs were
calculated by fitting the data to the appropriate Michaelis-Menten equations by using nonlin-
ear regression in Prism 6.0 software (GraphPad Software, USA). Values are the means of three
independent determinations.
Ethics statement
The study involved a retrospective analysis of participant serum samples left from routine
tests. Blood serum samples were collected from the 134 patients of the Institute for Experimen-
tal Medicine Medical Research Center for routine tests from January 6, 2016 till April 1 2016.
These serum samples included 16 sera from 24–39 years old persons, 31 sera from 40–59 years
old participants and 87 sera from patients aged 60–84 years. None of participants was vacci-
nated against influenza in 2016. Left sera were stored at -20˚C. After receiving the approval
from the Ethics Committee of the Institute for Experimental Medicine No. 2/16 of May 12,
2016, these sera were provided to study neuraminidase antibodies. We also tested the 42
archive serum samples obtained from non-vaccinated volunteers 20–59 years old in October
2010. The 15 paired sera from the convalescents with laboratory confirmed A/H1N1pdm09
influenza infections collected in January-February 2016 at hospitalization and 4–8 days later
were provided by The Institute of Influenza. The age of these patients was 19 to 83 years. Writ-
ten informed consent was obtained for each participant. The participants were fully informed
of the research procedures and any risks associated with participation, and consented to partic-
ipate in scientific projects.
None of the authors collected the samples used in the study, had access to information that
would allow the identification of individual patients during the extraction of data from medical
records, the data was de-identified before access by any of the authors.
Detection of serum antibodies against A/H1N1 viruses
HI test with blood sera was performed using a 0.75% suspension of human red blood cells
(Group “0”) in “U”-bottom 96-well polymer plates for immunological reactions using standard
procedures [18]. To remove thermo-labile inhibitors, the sera were heated at 56˚C for 30 min.
To remove thermo-stable hemagglutination inhibitors, the studied sera were treated with an
extract of Vibrio cholerae NA (Denka Seiken Co., Japan), and tested in duplicate for HI anti-
bodies with the following test antigens: A/South Africa/3626/13 (H1N1)pdm, A/California/07/
2009 (H1N1)pdm, A/New Caledonia/20/99 (H1N1), and A/Puerto Rico/8/34 (H1N1). The
titers of HI antibodies were expressed as the reciprocal of the highest serum dilution at which
HI was observed.
The production of anti-NA antibodies against A/California/07/2009 (H1N1)pdm and A/
South Africa/3626/13 (H1N1)pdm was evaluated in the sialidase activity inhibition test [19]
using the A/H7N1 and A/H6N1 reassortant viruses described above after purification and con-
centration on a stepwise 30/60% sucrose gradient. To assay anti-NI antibodies, 96-well plates
(Sarstedt AG & Co, Germany) were coated overnight with 150 μL of 50 μg/mL fetuin (Sigma-
Aldrich, USA). The purified A/H7N1 or A/H6N1 reassortants were adjusted in phosphate-
buffered saline (PBS) containing 1% bovine serum albumin (BSA) to obtain 128 hemagglutina-
tion units (HAU) and yielded 0.4–0.6 optical density at 450 nm (OD450). 65 μL of sera samples
were heated at 56˚C for 30 min, serially diluted in PBS-BSA, and incubated with an equal vol-
ume of pre-diluted virus for 30 min at 37˚C. After incubation, 100 μL of the mixture was
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added to the fetuin-coated wells. After 1 h incubation at 37˚C, the plates were washed, and NA
activity was measured by incubating with peroxidase-labeled peanut lectin (2.5 μg/mL, Sigma-
Aldrich, USA) for 1 h at room temperature followed by washing and adding 100 μL of peroxi-
dase substrate. The reaction was stopped after 5 min with 100 μL of 1 N sulfuric acid. OD val-
ues were measured at 450 nm using the universal microplate reader (ELx800, Bio-Tek
Instruments Inc, USA). The titer of serum NI antibodies was calculated as the reciprocal dilu-
tion of the sample with 50% inhibition of NA activity, i.e. two-fold decrease in optical density
in comparison with the virus control wells.
Determination of neutralizing antibodies against A/South Africa/3626/13 (H1N1)pdm was
carried out using the microneutralization (MN) test in the Madin-Darby canine kidney
(MDCK) cells with no-RDE-treated sera as described previously [18].
Statistical analysis
Data were analyzed using Statistica software, version 6.0 (StatSoft Inc., USA). The anti-
body titers were expressed as log2 of the inversed final dilution for statistical analysis.
Geometric mean titers (GMT), medians (Me) and lower and upper quartiles (Q1; Q3)
were calculated and used to represent the antibody levels. Comparisons of two indepen-
dent groups were made with nonparametric Kolmogorov-Smirnov 2-sample test. To
compare multiple independent groups, we used a Kruskal-Wallis analysis of variance
(ANOVA) with subsequent multiple pairwise comparisons based on Kruskal-Wallis sums
of ranks. Comparisons of two dependent variables were performed using Wilcoxon
matched pairs test. Fisher exact 2-tailed test was performed in case of nominal variables.
Non-parametric measure of statistical dependence between 2 variables was done using
Spearman’s rank correlation coefficient (r). The P-value < 0.05 was considered to be sta-
tistically significant.
Results
Analysis of NA amino acid sequences of A/H1N1 viruses
We used a distance method of proximity for the reconstruction of NA phylogenetic trees.
Based on the initial alignment we evaluated the stability of the tree topology using bootstrap
analysis using the results of the construction and comparison of phylogenetic trees gener-
ated for 1,000 sets of NA amino acid sequences. Our phylogenetic analysis of N1 amino acid
sequences demonstrated that the NA of A/California/07/09 (H1N1)pdm as well as the NA
of other viruses isolated after 2009 in North America and Asia exhibited similarity to the
phylogenetic branch of the swine viruses of the Euro-Asian lineage isolated in 2004 (Fig
1A). NA sequences of recent epidemic A/H1N1 viruses were more closely related to A/
H1N1 strains isolated in 1918 and 1943 compared with the A/H1N1pdm09 isolates. The
NAs of A/California/07/09 (H1N1)pdm and A/South Africa/3626/13 (H1N1)pdm were
98% identical and differed only by 10 amino acid substitutions, I34V, L40I, N44S, T135A,
N200S, V241I, N248D, I321V, N369K, K432E (N1 numbering here and throughout the
text), which do not alter NA polarity and/or charge. Mutations at residues 34, 40, and 44
were located in the NA stem, whereas the rest were located in the head domain outside the
active center (Fig 1B) [20].
We next determined NA activities of A/California/07/09 (H1N1)pdm and A/South Africa/
3626/13 (H1N1)pdm viruses by measuring NA enzyme Km and Vmax values for both A/
H1N1pdm09 strains and by using the fluorogenic MUNANA as a substrate (Fig 1C and
Table 1). Our data showed that NA protein of A/South Africa/3626/13 (H1N1)pdm exhibited
significantly higher affinity for the substrate (mean Km, 2.3-fold) than A/California/07/09
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(H1N1)pdm NA (P< 0.05). Furthermore, NA enzyme activity of A/South Africa/3626/13
(H1N1)pdm was significantly higher compared to that of A/California/07/09 (H1N1)pdm
(Vmax ratio = 1.6; Fig 1C and Table 1).
Fig 1. Analysis of N1 NA proteins. (A) Phylogenetic analysis of NAs originating from different A/H1N1 viruses isolated from human and swine (AA 1–469).
Phylogenetic analysis of amino acid sequences of NAs originating from different A/H1N1 viruses isolated from human and swine (AA 1–469). The sequences were
obtained from The NCBI Influenza Virus Sequence Database. Numbers of bootstrapping trees next to each node represent a measure of support for the node. (B)
Three-dimensional model of the NA “head” (AA 83–469) was created using Cn3D software. Seven amino acid substitutions that differ in the NA head domain of A/
California/07/09 (H1N1)pdm compared to A/South Africa/3626/13 (H1N1)pdm are shown in purple. (C) NA enzyme kinetics of A/California/07/09 (H1N1)pdm and
A/South Africa/3626/13 (H1N1)pdm viruses. Substrate conversion velocity (Vi) of NA was measured as a function of substrate concentration.
https://doi.org/10.1371/journal.pone.0196771.g001
Table 1. Enzymatic properties of A/H1N1pdm09 NAs.
Viruses Vmax (μM/min)a Km (μM)b
A/California/07/09 (H1N1)pdm 0.70 ± 0.02 34.35 ± 3.77
A/South Africa/3626/13 (H1N1)pdm 1.13 ± 0.02 78.45 ± 5.49
a The Vmax was calculated using a nonlinear regression of the curve according to the Michaelis-Menten equation.
b The Km represents the Michaelis-Menten constant (μM) at which the reaction rate is half of Vmax. The enzyme
kinetic data were fit to the Michaelis-Menten equation using GraphPad Prism, version 6.0. Values are the
means ± standard deviations from three independent determinations.
P< 0.05, compared to the values for the A/California/07/09 (H1N1)pdm virus by t-test.
https://doi.org/10.1371/journal.pone.0196771.t001
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Comparison of “herd” immunity against A/California/07/09 (H1N1)pdm
in 2010–2011 and 2015–2016 epidemic seasons
We compared the HI and NI antibody levels against A/California/07/09 (H1N1)pdm in the
sera collected from adult volunteers between 20–59 years of age. The sera were collected in
October 2010 (n = 42) and in January-March 2016 (n = 47). ANOVA test showed no differ-
ence in age distribution of the participants between both groups (P> 0.05). As seen in Fig 2,
the proportions of with NI antibody titers <1:40 and1:40 were similar between volunteers
examined in 2010 (i.e., one year after A/H1N1pdm09 emerged) and in 2016 (i.e., after 6 years
of A/H1N1pdm09 circulation).
Surprisingly, a number of subjects with HI antibody titers1:40 against A/California/07/09
(H1N1)pdm (i.e., level that is traditionally associated with at least a 50% reduction in the risk
of disease due to influenza infection) was significantly lower among volunteers examined in
2016 compared to 2010 (P = 0.047). These results may suggest decreased circulation of A/
H1N1pdm09 in 2016 compared to 2010.
Detection of HI and NI antibodies against A/South Africa/3626/13 (H1N1)
pdm and A/California/07/09 (H1N1)pdm in 134 blood donors examined
during the 2015–2016 epidemic season
The antibody levels against HA and NA of A/H1N1pdm09 viruses were examined among 134
patients of Medical Research Center. Since the examined subjects did not receive vaccination
against A/H1N1pdm09, it was assumed that the antibodies to surface antigens of A/
H1N1pdm09 viruses were acquired due to natural infection. Among all these subjects was
obtained statistically significant differences between HI antibody levels to A/South Africa/
3626/13 (H1N1)pdm in participants with influenza-like illnesses (ILI) compared with those
with no ILI (P = 0.0014, Fig 3A). With respect to A/California/07/09 (H1N1)pdm these differ-
ences were not statistically significant (P = 0.058). These data may suggest that the drift A/
H1N1pdm09 variant, presumably A/South Africa/3626/13-like, has already circulated in
St. Petersburg along with A/California/07/09 (H1N1)pdm during the period of the study.
Fig 2. The levels of “herd” immunity against A/California/07/09 (H1N1)pdm virus in 2009–2010 and 2015–2016
epidemic seasons among participants 20–59 years old. , P = 0.047.
https://doi.org/10.1371/journal.pone.0196771.g002
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As seen in Fig 3B, among all 134 volunteers 24–84 years of age, the majority of participants
had HI antibody titers <1:40 against A/South Africa/3626/13 (H1N1)pdm and A/California/
07/09 (H1N1)pdm. We observed similar proportions of subjects possessing HI antibody titers
1:40 against A/South Africa/3626/13 (H1N1)pdm and A/California/07/09 (H1N1)pdm
(5.2% and 9.7%; P> 0.05). Contrary data were obtained for NI antibodies: the NI antibody
titers1:40 against A/California/07/09 (H1N1)pdm were found in 33.6% of participants,
whereas only 2.2% of subjects demonstrated such NI antibodies levels against A/South Africa/
3626/13 (H1N1)pdm (P< 0.0001). The correlation between NI antibody titers against A/Cali-
fornia/07/09 (H1N1)pdm and A/South Africa/3626/13 (H1N1)pdm among 134 blood donors
was established as a link of medium strength: only 19.1% of the ranks variability in one variable
can be explained using the ranks of another variable (r = 0.437, n = 134, P< 0.05, Fig 3C).
The NI antibody titers against A/California/07/09 (H1N1)pdm and A/South Africa/3626/13
(H1N1)pdm better correlated (r = 0.640; n = 49; P< 0.0001) in the sera of the patients seropos-
itive to A/H1N1pdm viruses (Fig 3D)
Fig 3. The antibody levels against A/H1N1pdm09 viruses in 134 blood donors 24–84 years of age examined in 2016. (A) HI antibody titers against A/H1N1pdm09
viruses among participants with registered ILI or without ILI. GMT were calculated and used to represent the mean antibody levels. (B) Proportion of subjects with HI
and NI antibody titers against surface antigens originated from A/South Africa/3626/2013 (H1N1)pdm or A/California07/2009 (H1N1)pdm strains; , proportion of
subjects with NI antibody titers 1:40 against A/South Africa/3626/13 (H1N1)pdm and A/California/07/09 (H1N1)pdm differ significantly (P< 0.0001). (C)
Correlation analysis of NI antibodies against A/California/07/09 (H1N1)pdm versus A/South Africa/3626/13 (H1N1)pdm among blood donors. (D) Correlation
analysis of NI antibodies against A/California/07/09 (H1N1)pdm versus A/South Africa/3626/13 (H1N1)pdm among patients seropositive to A/H1N1pdm viruses.
https://doi.org/10.1371/journal.pone.0196771.g003
Anti-neuraminidase antibodies against pandemic A/H1N1 influenza in healthy and influenza-infected individuals
PLOS ONE | https://doi.org/10.1371/journal.pone.0196771 May 9, 2018 8 / 15
The low NI antibody titers against A/South Africa/3626/13 (H1N1)pdm and high NI anti-
body titers against A/California/07/09 (H1N1)pdm may suggest that the drift variant A/South
Africa/3626/13 (H1N1)pdm only started circulating in 2016. This finding may also indicate
that antibodies against A/South Africa/3626/13 (H1N1)pdm NA found in the blood donors
could result from direct infection with a new antigenic A/H1N1pdm09 variant rather than
from cross-reaction as a result of contact with previously circulating seasonal A/H1N1 vari-
ants. Thus, antibody levels against A/South Africa/3626/13 (H1N1)pdm NA were significantly
lower than against A/California/07/09 (H1N1)pdm NA among the 48 participants negative to
HA of A/H1N1pdm09 viruses but positive to A/New Caledonia/20/99 (H1N1) or A/Puerto
Rico/8/34 (H1N1) (P< 0.0001; Fig 4A) which HA amino-acid sequences differ more than
15% from A/California/07/09 (H1N1)pdm and A/South Africa/13 (Fig 4B). Since these
patients did not possessed antibodies against HA of A/H1N1pdm09 viruses, it is likely that the
detected antibodies to HA of previously circulated A/H1N1 viruses could be the result of anti-
genic ‘sin’. Despite the NA amino-acid sequences of A/South Africa/3626/13 (H1N1)pdm and
A/California/07/09 (H1N1)pdm were very similar (Fig 1A), the levels of “herd” immunity
against NA of A/H1N1pdm09 viruses in these patients varied significantly: NI antibody titers
1:40 were detected in 29.1% against A/California/07/09 (H1N1)pdm and were not found
against A/South Africa/3626/13 (H1N1)pdm (P<0.01).
Comparative analysis of the antibodies against A/H1N1 in patients of
different ages
The age distribution of A/H1N1-specific antibodies was analyzed in several participant age
groups: subjects born prior to 1957, when only A/H1N1 viruses were circulating; subjects born
between 1957–1976 when A/H2N2 and A/H3N2 viruses were circulating, and subjects born in
1977 and later, when A/H1N1 re-emerged and began co-circulating along with A/H3N2
(Table 2).
The highest levels of anti-HA antibodies against seasonal A/New Caledonia/20/99 (H1N1)
and both A/H1N1pdm09 viruses were detected in the 24–39 age group compared to elder peo-
ple (P = 0.023). Participants between 60–84 years of age demonstrated the lowest level of HI
antibodies against A/New Caledonia/20/99 (H1N1), slightly increased HI titers against A/
Fig 4. Analysis of the sera from 48 participants negative to HA of A/H1N1pdm09 viruses, but positive to A/New Caledonia/20/99 (H1N1) or A/Puerto Rico/8/34
(H1N1). (A) NI antibody levels against A(H1N1)pdm09 viruses. (B) Distance matrix of the A/H1N1 influenza viruses HA amino-acid sequences. Matrix shows identity
between influenza virus strains.
https://doi.org/10.1371/journal.pone.0196771.g004
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Puerto Rico/8/34 (H1N1) and the highest NI antibody titers against A/California/07/09
(H1N1)pdm compared with other groups (P< 0.0001) (Table 2). Our data confirm earlier
findings that older people, who had been in contact with A/H1N1 viruses that have not been
in circulation for a long time, may demonstrate antigenic “sin” when infected with recent
viruses [21, 22]. In this case, the priming antibodies are formed not only to the infecting virus
but also to the previous variants. However, the question of the protective role of these antibod-
ies still remains unclear. On one hand, the presence of such antibodies can make a definite
contribution to the protection against infection with a new antigenic variant [23]. On the
other hand, there is evidence that pre-existing antibodies to previously circulating variants
may somehow prevent the development of protective antibodies in infection with the new
antigenic variants [24].
The lowest levels of NI antibodies against A/California/07/09 (H1N1)pdm and no NI
antibodies against A/South Africa/3626/13 (H1N1)pdm were found in people 40–59 years
old who were born from 1956 to 1976, when the H2N2 and H3N2 viruses were in circula-
tion (Table 2).
Analysis of sera samples from the convalescents
We included the 15 paired sera from the patients with laboratory-confirmed A/H1N1pdm09
infection. We observed that mean HI and NI antibody titers against A/California/07/09
(H1N1)pdm were significantly higher on days 4–7 after the onset of symptoms compared to
those on date of onset (P = 0.01, P = 0.015, respectively) (Fig 5A). HI and NI antibody titers
against A/South Africa/3626/13 (H1N1)pdm increased as the disease progressed (P = 0.02,
P = 0.043). Seven of 15 participants (46%) had the 4-fold HI antibody increase either against
A/California/07/09 (H1N1)pdm or A/South Africa/3626/13 (H1N1)pdm with 6 participants
responding simultaneously to both viruses. Sera collected from 5 participants with increased
post-infection NI antibodies >1:40 reacted with A/South Africa/3626/13 (H1N1)pdm in the
HI test.
Because the virus neutralization by antibodies in vitro often reflects the biological effect of
protective antibodies and the MN test is known to correlate well with the HI assay [25], we
compared results of HI and NI titers with the MN antibody titers determined when A/South
Africa/3626/13 (H1N1)pdm was used as an antigen. A strong relationship was found between
Table 2. Antibodies against HA and NA of A/H1N1 viruses among 134 subjects of different ages examined in 2016.
Year of
birth
No. of participants in
the group
HI antibodies NI antibodies
A/South Africa/ 3626/
13 (H1N1)pdm
A/California/07/09
(H1N1)pdm
A/NC A/PR/8 A/South Africa/ 3626/
13 (H1N1)pdm
A/California/07/09
(H1N1)pdm
(log2, Me, Q1; Q3) (log2, Me, Q1; Q3) (log2, Me,
Q1; Q3)
(log2, Me,
Q1; Q3)
(log2, Me, Q1; Q3) (log2, Me, Q1; Q3)
1977 and
later
16 2.8 (2.3; 3.8) 3.3 (2.3; 4.8) 4.3 (2.3;
5.3)
2.8 (2.3; 3.3) 2.3 (2.3;2.3) 4.2 (4.2;5.6)
1957–
1976
31 2.3 (2.3; 3.3) 3.3 (2.3; 4.3) 3.3 (2.3;
4.3)
2.3 (2.3; 3.3) 2.3 (2.3; 3.3) 2.3 (2.3; 3.8)
Before
1957
87 2.3 (2.3; 3.3) 2.3 (2.3; 3.3) 2.3 (2.3; 3.3) 3.3 (2.3; 4.3) 2.3 (2.3; 2.3) 4.9 (3.4;6.4)
Note: (Me–medians; Q1; Q3—lower and upper quartiles).
, P = 0.023 compared to subjects born before 1957
, P = 0.046 compared to subjects born before 1957
, P = 0.00007 compared to subjects born in 1957–1976.
https://doi.org/10.1371/journal.pone.0196771.t002
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neutralizing antibody titers and HI antibody titers against A/South Africa/3626/13 (H1N1)
pdm (r = 0.705, n = 30, P< 0.0001), whereas a medium relationship was found between neu-
tralizing antibody titers and NI antibodies against A/South Africa/3626/13 (H1N1)pdm
(r = 0.579, P< 0.0001) as determined by Pearson correlation test (Fig 5B and 5C). A medium
relationship was observed between neutralizing antibody titers against A/South Africa/3626/
13 (H1N1)pdm and HI antibody titers against A/California/07/09 (H1N1)pdm (r = 0.670,
n = 30, P< 0.0001) as well as between MN antibody titers against A/South Africa/3626/13
(H1N1)pdm and NI antibody titers against A/California/07/09 (H1N1)pdm (r = 0.647, n = 30,
P< 0.0001) (Fig 5D and 5E). These data suggest that anti-NA antibodies may be virus-neutral-
izing along with anti-hemagglutinating antibodies.
Fig 5. The antibody levels against A/H1N1pdm09 viruses in paired sera from the A/H1N1pdm09-infected patients (n = 15). (A)
Increase in antibody titers against A/California/07/2009 (H1N1)pdm as determined by HI and NI assays and against A/South Africa/3626/
2013 (H1N1)pdm as determined by HI and, NI, and MN assays. The antibody titers were expressed as log2. (B) Correlation between MN
and HI antibodies against A/South Africa/3626/13 (H1N1)pdm in sera collected from the convalescents. (C) Correlation between MN and
NI antibodies against A/South Africa/3626/13 (H1N1)pdm in sera collected from the convalescents. (D) Correlation between MN
antibodies against A/South Africa/3626/13 (H1N1)pdm and HI antibodies against A/California/07/2009 (H1N1)pdm in sera collected from
the convalescents. (E) Correlation between MN antibodies against A/South Africa/3626/13 (H1N1)pdm and NI antibodies against A/
California/07/2009 (H1N1)pdm in sera collected from the convalescents. The “r” means Spearman’s rank correlation coefficient.
https://doi.org/10.1371/journal.pone.0196771.g005
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Discussion
Our data suggested that a small number of patients examined in the present study may have
been infected with A/South Africa/3626/13-like influenza viruses by March 2016 and this
resulted in the induction of homologous HI and NI antibodies. Contact with previously circu-
lated A/H1N1 viruses did not induce cross-reactive NI antibodies against A/South Africa/
3626/13 (H1N1)pdm, but induced NI antibodies cross-reactive with A/California/07/09
(H1N1)pdm. Our survey revealed a low level of detectable NI antibodies against new antigenic
A/H1N1pdm09 variant (5.2%), especially in light of the fact that pandemic viruses have been
circulating in Russia for more than 6 years. As it was shown in our previous work [26], even in
2005, i.e. long before the appearance of A/H1N1pdm09 in humans, the level of cross-reactive
antibodies against A/California/07/09 (H1N1)pdm NA with titers1:20 was 7.1%, and after
the introduction of the virus into circulation it increased up to 30% and later up to 53% in
2016. The levels of “herd” immunity against NA, as determined by the number of subjects
with NI antibody titers1:40 against the A/South Africa/3626/13 (H1N1)pdm were low com-
pared to those against A/California/07/09 (H1N1)pdm (Fig 3B). One explanation of these
results could be antigenic differences between NAs of the two pandemic viruses. As previously
reported, even a single amino acid change within an immunodominant epitope may lead to
loss of reactivity with polyclonal antisera [27]. For example, introduction of a single NA amino
acid change in A/Solomon Islands/3/2006 strain at position 329 resulted in reduced enzyme
inhibition by ferret and human sera directed against this virus [28]. The amino acid sequences
of the A/California/07/09 (H1N1)pdm NA and A/South Africa/3626/13 (H1N1)pdm NA dif-
fered by 2% and 7 substitutions were located in the head domain, outside the active center.
The substitutions N372K and K432E were located in the portion from the second binding site,
commonly found in N6 and N9 avian influenza viruses [29]. When MUNANA was used as a
substrate, A/California/07/09 (H1N1)pdm NA exhibited significantly decreased NA activity
compared to that of A/South Africa/3626/13 (H1N1)pdm (Fig 1C, Table 1). These results may
suggest that there is interplay between enzyme activity and antigenicity of N1 NA protein. Our
finding may also explain the ineffective inhibition of A/South Africa/3626/13 (H1N1)pdm NA
by cross-reactive NI antibodies induced against previously circulated A/H1N1 viruses, includ-
ing A/California/07/09 (H1N1)pdm.
Previously it has been reported that anti-HA stalk monoclonal antibodies bind to H6 HA
reducing the NA activity of the reassortant H6NX viruses through steric interactions [22] thus
affecting the results of the NI reaction. Despite the fact that we used A/H6N1 reassortant virus
in one case and A/H7N1 in the other case to NI test, the data can still be comparable since the
HA stalk domain is highly conservative [30]. We assume that the difference in NI antibody lev-
els against A/California/07/09 (H1N1)pdm and A/South Africa/3626/13 (H1N1)pdm in the
population as a whole can be attributed to the presence of cross-reactive, rather than homolo-
gous, antibodies to a drift A/H1N1pdm09 variant. This was confirmed by the data from the A/
H1N1pdm-positive patients, when the correlation between NI antibody levels against A/Cali-
fornia/07/09 (H1N1)pdm and A/South Africa/3626/13 (H1N1)pdm were more pronounced
compared to the population at a whole (Fig 3D). Analyzing the sera of patients soon after the
influenza infection we showed that the immune responses to both influenza surface antigens
were induced simultaneously right after natural infection with A/H1N1pdm09 viruses (Fig 5A
and 5B). Some autonomy of the HI and NI immune responses among those subjects who have
been exposed to the virus in the past may be related to the timing of the material sampling,
particularly when detecting anti-NA antibodies.
Influenza infection represents a particular risk of complications and increased mortality in
the elderly. The disease is characterized by a combination of inflammatory changes in the
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upper respiratory tract with general intoxication and damage to the nervous and cardiovascu-
lar systems, thus causing severe complications when developed against the background of ath-
erosclerotic changes in the cardiovascular system and other chronic conditions [31]. In a
number of previous studies, the NI antibody titers against A/H1N1pdm09 were detected in the
sera of older individuals [32], possibly explaining the reported low incidence of A/
H1N1pdm09 disease in the elderly [33]. Indeed, the importance of NA immunity against natu-
rally occurring influenza was demonstrated by evaluating HI and NI antibody titers in a study
conducted during 2009–2011 [34] when increased serum NI titers were associated with
reduced illnesses. Elderly individuals who were likely exposed to 1918 Spanish Flu pandemic
had high neutralizing titers against A/H1N1pdm09 [21] and were more likely to possess cross-
reactive antibodies against A/H1N1pdm09 N1 NA. In the present study, we did not observe
significant difference in HI and NI antibody levels against A/South Africa/3626/13 (H1N1)
pdm among individuals born before 1957 compared to the younger subjects. In contrast, the
highest levels of NI antibodies against A/California/07/09 (H1N1)pdm were found in the older
age group compared to other groups studied. Thus, the highest levels of NI antibodies against
A/California/07/09 (H1N1)pdm may be attributed to cross-reactive antibodies against A/
H1N1 viruses other than A/H1N1pdm09. A group of middle-aged patients with the lowest
level of NI antibodies against a new antigenic A/H1N1pdm09 variant was identified, indicating
the highest-priority vaccination against new antigenic variants.
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